FindTrial
Sign In

Nanrilkefusp alfa

DRUG3 trials

Sponsors

SOTIO Biotech AG

Conditions

Anal CancerBiliary Tract CancerBladder CancerCastration-resistant Prostate CancerCervical CancerColorectal CancerCutaneous Squamous Cell CarcinomaGastric Cancer

Phase 1

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
TerminatedNCT04234113
SOTIO Biotech AGAnal Cancer, Biliary Tract Cancer, Bladder Cancer +16
Start: 2019-06-13End: 2024-11-27Updated: 2026-03-27

Phase 2

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
TerminatedNCT05256381
SOTIO Biotech AGCastration-resistant Prostate Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma +3
Start: 2022-06-21End: 2024-11-29Updated: 2025-11-17
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
TerminatedNCT05619172
SOTIO Biotech AGColorectal Cancer
Start: 2022-12-22End: 2024-06-05Updated: 2025-07-24

Related Papers

Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers.
2025-02-101 citations
713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers
Regular and Young Investigator Award Abstracts2023-10-311 citations
716 AURELIO-04: a phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients with selected advanced solid tumors
Regular and Young Investigator Award Abstracts2022-11-012 citations
Abstract CT040: SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial
Cancer Research2022-06-152 citations
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
Journal of Clinical Oncology2022-06-0113 citations
484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors
Regular and Young Investigator Award Abstracts2021-11-012 citations
502 Recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the IL-15 superagonist SO-C101 as monotherapy in patients with advanced/metastatic solid tumors
Regular and Young Investigator Award Abstracts2021-11-01
510 SO-C101, a high-affinity IL-15Rbg agonist, induces safe and potent anti-tumor immune activities in patients with solid tumors and supports further clinical investigations
Regular and Young Investigator Award Abstracts2021-11-01
807 A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
2020-11-012 citations
563 Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys
Regular and Young Investigator Award Abstracts2020-11-011 citations